Trial Number


Participant Age Range

50 years and older

Participant Gender


Enrolling Participants



The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population

The purpose and rationale is to evaluate the safety and performance of the GRAIL Multi-Cancer Early Detection (MCED) Test in an eligible screening population.  All participants will be actively followed by the enrolling institution for 3 years to assess for cancer status, uptake of routine cancer screening and other data collection with analyses performed at interim time points. In addition to a baseline questionnaire, additional participant-reported outcomes will be collected at multiple time points before and after test results are returned.


Related Clinical Trials

Click on the category you are interested in.

Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.